Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1982 2
1983 2
1984 2
1985 3
1986 3
1987 2
1988 3
1989 1
1990 4
1992 1
1994 1
1998 1
2000 1
2005 2
2009 1
2012 1
2018 4
2019 4
2021 3
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.
Adès L, Girshova L, Doronin VA, Díez-Campelo M, Valcárcel D, Kambhampati S, Viniou NA, Woszczyk D, De Paz Arias R, Symeonidis A, Anagnostopoulos A, Munhoz EC, Platzbecker U, Santini V, Fram RJ, Yuan Y, Friedlander S, Faller DV, Sekeres MA. Adès L, et al. Among authors: fram rj. Blood Adv. 2022 Sep 13;6(17):5132-5145. doi: 10.1182/bloodadvances.2022007334. Blood Adv. 2022. PMID: 35728048 Free PMC article. Clinical Trial.
Bone metastases.
Hamdalla H, Fram RJ. Hamdalla H, et al. Among authors: fram rj. Med Health R I. 2000 Apr;83(4):112-3. Med Health R I. 2000. PMID: 10821011 No abstract available.
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Sekeres MA, Watts J, Radinoff A, Sangerman MA, Cerrano M, Lopez PF, Zeidner JF, Campelo MD, Graux C, Liesveld J, Selleslag D, Tzvetkov N, Fram RJ, Zhao D, Bell J, Friedlander S, Faller DV, Adès L. Sekeres MA, et al. Among authors: fram rj. Leukemia. 2021 Jul;35(7):2119-2124. doi: 10.1038/s41375-021-01125-4. Epub 2021 Jan 22. Leukemia. 2021. PMID: 33483617 Free PMC article. Clinical Trial. No abstract available.
Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Sekeres MA, Watts J, Radinoff A, Sangerman MA, Cerrano M, Lopez PF, Zeidner JF, Campelo MD, Graux C, Liesveld J, Selleslag D, Tzvetkov N, Fram RJ, Zhao D, Bell J, Friedlander S, Faller DV, Adès L. Sekeres MA, et al. Among authors: fram rj. Leukemia. 2021 Dec;35(12):3637. doi: 10.1038/s41375-021-01473-1. Leukemia. 2021. PMID: 34789825 Free PMC article. No abstract available.
44 results